Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday.

Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to close at $2.42 apiece and bucking the decline in the overall healthcare sector, as investors continued to load up positions following the addition of two CEOs in its board.

Early last week, Vor Biopharma Inc. (NASDAQ:VOR) announced the addition of Alexander Cumbo and Michel Detheux to its board of directors, sparking confidence among investors amid ongoing efforts to strengthen leadership and strategic direction.

Cumbo currently serves as president and CEO of Solid Biosciences. He was also the founding CEO of AavantiBio and brings more than 30 years of commercial and executive leadership, including nearly eight years at Sarepta Therapeutics, where he most recently served as Executive Vice President and Chief Commercial Officer.

Meanwhile, Detheux is the president and CEO of iTeos Therapeutics. Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company’s lead anti-TIGIT antibody.

In a statement, Vor Biopharma Inc. (NASDAQ:VOR) said that Cumbo and Detheux’s addition is invaluable as the company advances telitacicept through late-stage development and expands its long-term vision to bring transformative therapies to patients with autoimmune disease.

While we acknowledge the potential of VOR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.